Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 3/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 2/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18064370 | 0.79 | CHEK1 (0.41) | CA1CA2CA12CA4CA7 | |
| SCHEMBL31568209 | 0.77 | CA1 (0.41) | CA1CA2CA12CA4CA7 | |
| SCHEMBL19411583 | 0.69 | PIK3CD (0.44) | CA1CA2CA12CA4CA7 | |
| SCHEMBL24697302 | 0.67 | CA2 (0.44) | CA1CA2CA12CA4CA7 | |
| SCHEMBL31568291 | 0.67 | CA2 (0.44) | CA1CA2CA12CA4CA7 | |
| SCHEMBL30017044 | 0.66 | RAF1 (0.40) | CA1CA2CA12CA4CA7 | |
| SCHEMBL31524271 | 0.63 | BACE2 (0.40) | CA1CA2CA12CA4CA7 | |
| SCHEMBL20423243 | 0.63 | TDP2 (0.49) | CA1CA2CA4CA7CA9 | |
| SCHEMBL21032172 | 0.63 | CA1 (0.37) | CA1CA2CA12CA4CA7 | |
| SCHEMBL31097877 | 0.63 | TDP2 (0.49) | CA1CA2CA4CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873690-B2 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | PFIZER INC (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160272628-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PFIZER INC. | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272628-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | CA1 3464/4885CA2 3049/4885CA12 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.